BVI's FINEVISION® HP Gains FDA Approval, Ushering in a New Era of Advanced Trifocal IOLs for U.S. Patients

BVI's FINEVISION® HP Gains FDA Approval, Ushering in a New Era of Advanced Trifocal IOLs for U.S. Patients

Milestone strengthens the company's leadership in advanced IOL innovation FINEVISION HP, with millions of implantations worldwide, will now be available to U.S. patients Proprietary design features anchor the launch of BVI's expanded U.S. IOL portfolio WALTHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BVI, a global leader in ophthalmic device innovation, today announced that the U.S. Food and Drug Administration (FDA) has approved its FINEVISION…

BVI Receives FDA Approval for Finevision HP Trifocal IOL

BVI announced that the FDA has approved its Finevision HP trifocal IOL.  According to BVI, Finevision HP was the world’s first trifocal IOL, with more than 15 years of clinical success and millions of implantations worldwide. Finevision HP was developed through the work of Christophe Pagnoulle, BVI’s Director of R&D, and Damien Gatinel, MD, PhD, ophthalmologist and vision science innovator. “The development of Finevision HP was a pivotal moment …